FGEN241220P1500
- 0.00
- 0.000.00%
FibroGen Newsroom
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 34% Share Price Rise
FibreGen Shares Are Trading Higher. The Stock May Be Moving on Continued Strength Following a Q3 Earnings Beat Reported on Tuesday.
Express News | FibreGen Shares Are Trading Higher. The Stock May Be Moving on Continued Strength Following a Q3 Earnings Beat Reported on Tuesday
FibroGen Reports Strong Q3 Growth and Future Plans
FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript Summary
FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript
Express News | FibroGen Inc: Expect Our Cash, Cash Equivalents and Accounts Receivable to Be Sufficient to Fund Our Operating Plans Into 2026
FibroGen | 8-K: FibroGen Reports Third Quarter 2024 Financial Results
Express News | FibroGen Reiterates Full Year Net Product Revenue Guidance Of $135M-$150M
FibroGen GAAP EPS of -$0.17 Beats by $0.06, Revenue of $46.3M Beats by $11.54M
Earnings Flash (FGEN) FIBROGEN Reports Q3 Loss $-0.17
FibroGen | 10-Q: Q3 2024 Earnings Report
Express News | FibroGen Q3 Net Income USD -17.084 Million
Press Release: FibroGen Reports Third Quarter 2024 Financial Results
FibroGen 3Q Rev $46.3M >FGEN
Earnings Preview: FibroGen to Report Financial Results Post-market on November 12
FibroGen to Report Third Quarter 2024 Financial Results
FibroGen, Inc. (NASDAQ:FGEN) Not Doing Enough For Some Investors As Its Shares Slump 27%
FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August